#Netherlands #diagnostics #Rotterdam #SkylineDx #BioTech Breakthrough

SkylineDx Wins Prestigious BioTech Award

SkylineDx, a pioneering diagnostics firm, has garnered the title of 'Diagnostics Company of the Year' in the 2025 BioTech Breakthrough Awards, celebrating its unwavering dedication to enhancing the quality of molecular diagnostics in oncology and other critical health sectors. The award acknowledges SkylineDx’s substantial achievements in the realm of genomic assays, particularly focusing on tests such as the Merlin CP-GEP Test for cutaneous melanoma and the SKY92 test for multiple myeloma.

Revolutionizing Diagnostics in Oncology

Founded to address the growing needs within the oncology sector, SkylineDx applies advanced molecular diagnostics research to the complexities of cancer treatment. In the words of CEO Dharminder Chahal, “At SkylineDx, we’re not just developing diagnostics – we’re changing how patients and doctors navigate critical treatment decisions together.” This statement reflects the company's mission to empower patients through personalized insights, guiding informed choices crucial to their care journey.

The Merlin CP-GEP Test is a noteworthy example of this innovative approach. It is a genomic assay that strategically assists health professionals in managing melanoma at all stages by combining clinicopathologic factors with gene expression analysis, effectively delineating patients' risks of metastasis. Commercially available in both the U.S. and Europe, this test stands at the forefront of melanoma management and has received validation through a landmark study published in JAMA Surgery. This study confirmed its efficacy in accurately stratifying melanoma patients based on the risk of sentinel node metastasis, thereby meeting essential standards of care in oncology.

A Comprehensive Approach to Molecular Diagnostics

SkylineDx’s commitment to advancing healthcare solutions is further exemplified by its array of programs tailored to various cancer types. The company conducts extensive evaluations of biomarkers before they are included in research and development programs, ensuring the selection of the most promising molecular diagnostics. Their STRIX Program embodies a systematic approach, harnessing interdisciplinary teams to explore and validate hundreds of potential biomarkers annually.

In addition to the Merlin tests, the company focuses on hematological malignancies through its Panthera Program, which includes the SKY92 test developed in collaboration with Erasmus MC. The Falcon Program aims at uncovering intricate insights into various skin cancers, ensuring that the company's diagnostic solutions are not only innovative but also clinically relevant.

Recognition from BioTech Breakthrough

BioTech Breakthrough, a renowned market intelligence organization, noted SkylineDx’s significant contributions to the medical community. Managing Director Bryan Vaughn emphasized that the company's multifaceted diagnostic solutions address fundamental healthcare challenges, particularly relating to the timely treatment of melanoma. He stated, “Patients need improved diagnostic systems to get the right treatments as soon as possible.” This recognition from BioTech Breakthrough serves to elevate SkylineDx’s status as a leader in biotechnology, showcasing its effective blend of scientific innovation and practical healthcare solutions.

As part of a larger global initiative, the BioTech Breakthrough Awards program received thousands of nominations this year, further affirming SkylineDx’s position in the competitive life sciences landscape. The honors aim to spotlight organizations that are paving the way in the biotechnology field, demonstrating excellence in their respective sectors.

The Future of SkylineDx

Looking ahead, SkylineDx aims to expand its influence within the molecular diagnostics field and continue bridging the gap between academic discoveries and commercially viable diagnostic solutions. The company’s operations are not limited to the Netherlands, as it maintains a robust presence in the U.S. through its CAP/CLIA certified laboratory in San Diego. This operational framework ensures comprehensive support to healthcare professionals across the nation, enhancing patient care in real time.

In summary, the recognition of SkylineDx as 'Diagnostics Company of the Year' encapsulates its commitment to revolutionizing healthcare through cutting-edge molecular diagnostics. As the company continues to push the boundaries of innovation, it remains dedicated to improving patient outcomes and redefining approaches to cancer treatment through personalized medicine.